News: Immunotherapy

The Tennessee Valley Healthcare System performed its first CAR-T infusion recently at the Veterans Administration hospital in Nashville.

GE Healthcare has awarded researchers $2.5 million in funding to develop PET tracer that will determine the effectiveness of immunotherapy in patients early in their treatment course.

Combining immunotherapy and radiation therapy may be a powerful treatment approach for castration-resistant prostate cancer.

Researchers are chronicling rare but serious toxicities that may occur with immune checkpoint inhibitors, the most widely prescribed class of immunotherapies.

A study published June 17 in Nature offers clues as to why blocking inhibitory receptors on tumor-infiltrating T cells may not always work

Immunotherapy is helping cancer patient Roszell Mack Jr. to continue going to his job on a Kentucky horse farm.

Some cancer patients receiving CAR-T infusions can now avoid hospital stays because of a telemedicine program launched by Vanderbilt-Ingram Cancer Center.

Researchers have discovered that a new “checkpoint” protein on immune system cells is active in tumors, and that blocking it — in combination with other treatments — is a successful therapeutic approach in mouse models of cancer.

Immunotherapies that take off the “brakes” on the adaptive anti-tumor response have worked well in melanoma and lung cancer but less so in breast cancers. That could change.

A recent study in the journal Cancer Research demonstrates that a RIG-I agonist has potent immunogenic and therapeutic effects in breast cancer.